mAbs have been raised that with both G250 and anti-CD3 specificity, resulting in crosslinking and G250 expressing RCC cells and T cells.

    Cytotoxicity assays show that the chimeric bispecific mAb is capable of mediating cell lysis of RCC cell lines by cloned human CD8+ T cells or by IL-2 stimulated peripheral blood lymphocytes (PBLs), and mediated lysis was effective at concentrations as low as 0.01 mg per ml.

hhere are the results of some cytotoxicity assays using bispecific G250/anti-CD3 mAbs:
Luiten et al.: Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.  British Journal of Cancer, 74: 734-744, 1996

        In this assay the cytotoxicity of murine and chimeric bispecific G250/anti-CD3 mAbs are compared with no mAb treatment, using RCC cell line A704 targets and human T cell clone, TIL 7.9
        Chimeric mAbs do not elecit a HAMA response as do murine mAbs.

asdfasdfasdfasfasdfasdf
 
 
 
 
 
 
 
 
 

Here's another assay using donor PBLs and only chimeric mAbs:
Luiten et al.: Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.  British Journal of Cancer, 74: 734-744, 1996

    PBLs from 3 different donors (A,B,C) were assayed in the illustrated E/T ratio's, with and without the bispecific chimeric mAbs in wells with 2000 targets per well.  The RCC cell line A704 was used in this assay, and those wells w/mAbs were incubated at concentrations of 1 mg per ml.